At present, several technical criticisms have been raised regarding the use of CPS as an indicator of PDL1 expression in head and neck carcinomas, which are related to the different clones of the PDL1 antibody used for lung carcinomas and the poorly defined cut-off level for positivity. This evidence concerns the gene CD274 and lung carcinoma.